August 25, 2010
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

August 20, 2010
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Bioniche Life Sciences Inc. is a leading, fully-integrated biopharmaceutical company that discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide.

Media Coverage

For recent media coverage of Bioniche Life Sciences Inc. click here >>

Latest News

August 25, 2010
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology more...

August 20, 2010
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010 more...

June 23, 2010
Bioniche & Trophogen Sign Exclusive Global Veterinary License Agreement for Superagonist Hormone Technology Platform more...

More News

Bioniche Key Facts

Founded: 1979

Chairman, President & CEO:
Graeme McRae

TSX stock symbol:
BNC

Fiscal year-end:
June 30

2009 revenues:
C$33.3 million

Headquarters:
Belleville, Ontario

Employees worldwide:
200

Business divisions:
Human Health,
Animal Health,
Food Safety

Focus areas:
Human Health:
cancer, immunomodulation

Animal Health:
reproduction, vaccines, replacement of antibiotics

Food Safety: E. coli O157 vaccine, other veterinary biopharmaceutical products to address diseases in livestock which may have an effect on human health

Top products:

Animal Health:
Folltropin®-V, MAP®-5